Healthcare | June 03, 2026
Cipla launches India's first sputum inflammometry lab in Mumbai
The facility sets a new benchmark in respiratory diagnostics
The facility sets a new benchmark in respiratory diagnostics
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Company to launch product after the expiry of semaglutide patent in India
_256_384.jpg)
Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
